| Agreement between Quantiferon-TB gold test and tuberculin skin test in the identification of latent tuberculosis infection in patients with rheumatoid arthritis and ankylosing spondylitis. | |
| | |
MedLine Citation:
|
PMID: 19918035 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To compare the Quantiferon-TB Gold test (QTF-G) with the tuberculin skin test (TST) for the detection of latent tuberculosis infection (LTBI) among patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS), with reevaluation of the patients treated with tumor necrosis factor-alpha (TNF-alpha) antagonists in the followup. METHODS: The study involved 140 consecutive patients, 82 with RA and 58 with AS. Thirty patients were evaluated with QTF-G for detection of LTBI before and after 6 months of TNF-alpha antagonist treatment. QTF-G was also performed on 49 healthy controls. QTF-G results were recorded as positive, negative, or indeterminate. A positive TST was defined as >or= 5 mm for RA and AS. RESULTS: The percentages of positive QTF-G were comparable in RA and AS (37% vs 32%). The rate of positive QTF-G in healthy controls (29%) was also similar to RA and AS. In contrast to QTF-G results, a high rate of TST positivity was observed in AS compared to RA (82% vs 55%; p = 0.02). The total agreement between QTF-G and TST was observed to be 61% (kappa = 0.29) in the whole group, 70% (kappa = 0.42) in RA, and 49% (kappa = 0.14) in AS. After 6 months of treatment with TNF-alpha antagonists, a high rate of QTF-G change was observed in patients with indeterminate results (23% vs 3%; p = 0.03). CONCLUSION: The comparable prevalence of LTBI among the study groups according to QTF-G supports the view that QTF-G is less susceptible to external factors than TST. Sequential testing for QTF-G in patients with indeterminate or negative results may also be helpful in discriminating LTBI better. |
| | |
Authors:
|
Nevsun Inanc; Sibel Zehra Aydin; Sait Karakurt; Pamir Atagunduz; Sule Yavuz; Haner Direskeneli |
Related Documents
:
|
10908695 - Major histocompatibility complex phenotypes influence serum testosterone concentration. 16095115 - A retrospective study of the fluctuation in serum levels of anti-cyclic citrullinated p... 11093435 - The effect of hla-drb1 genes, rheumatoid factor, and treatment on radiographic disease ... 16518665 - Combined use of propagation velocity and intraventricular dispersion of e wave velocity... 21120685 - Icf syndrome in saudi arabia: immunological, cytogenetic and molecular analysis. 20484935 - Elevated urinary fibronectin excretion predicts poor outcome in patients with primary c... |
Publication Detail:
|
Type: Evaluation Studies; Journal Article Date: 2009-11-16 |
Journal Detail:
|
Title: The Journal of rheumatology Volume: 36 ISSN: 0315-162X ISO Abbreviation: J. Rheumatol. Publication Date: 2009 Dec |
Date Detail:
|
Created Date: 2009-12-07 Completed Date: 2010-02-05 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7501984 Medline TA: J Rheumatol Country: Canada |
Other Details:
|
Languages: eng Pagination: 2675-81 Citation Subset: IM |
Affiliation:
|
Division of Rheumatology, Department of Pulmonary and Critical Care, Marmara University Medical School, Istanbul, Turkey. inanc.nevsun@gmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antirheumatic Agents / immunology, therapeutic use Arthritis, Rheumatoid / complications, drug therapy, immunology* Female Humans Latent Tuberculosis / diagnosis*, etiology, immunology Male Middle Aged Risk Factors Spondylitis, Ankylosing / complications, drug therapy, immunology* Tuberculin Test / methods* Tumor Necrosis Factor-alpha / antagonists & inhibitors |
| Chemical | |
Reg. No./Substance:
|
0/Antirheumatic Agents; 0/Tumor Necrosis Factor-alpha |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Malignancy Is Associated with Dermatomyositis But Not Polymyositis in Northern New England, USA.
Next Document: Lack of Association Between IRF5 Gene Polymorphisms and Biopsy-proven Giant Cell Arteritis.